Cargando…

Subgroup analysis reveals higher reliability of the new comprehensive evaluation of Global Initiative for Chronic Obstructive Lung Disease 2019

To estimate the severity of the disease in outpatients with chronic obstructive pulmonary disease (COPD) in Hunan Province, China and use the subgroup analysis to evaluate the reliability of the new comprehensive evaluation of Global Initiative for Chronic Obstructive Lung Disease (GOLD). COPD outpa...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Zhongshang, Zeng, Huihui, Cui, Yanan, Chen, Ping, Chen, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760288/
https://www.ncbi.nlm.nih.gov/pubmed/35031681
http://dx.doi.org/10.1038/s41598-021-04756-w
_version_ 1784633286578929664
author Dai, Zhongshang
Zeng, Huihui
Cui, Yanan
Chen, Ping
Chen, Yan
author_facet Dai, Zhongshang
Zeng, Huihui
Cui, Yanan
Chen, Ping
Chen, Yan
author_sort Dai, Zhongshang
collection PubMed
description To estimate the severity of the disease in outpatients with chronic obstructive pulmonary disease (COPD) in Hunan Province, China and use the subgroup analysis to evaluate the reliability of the new comprehensive evaluation of Global Initiative for Chronic Obstructive Lung Disease (GOLD). COPD outpatients from 12 medical centers in Hunan Province, China were stratified into groups A–D, and group D patients were further stratified into subgroups D(1)–D(3) according to the GOLD 2016 and 2019 comprehensive assessment. Demography, clinical characteristics and medications were compared among groups. In 1017 COPD outpatients, the distribution from group A to D and subgroup D(1) to D(3) was 41 (4.0%), 249 (24.5%), 17 (1.7%), 710 (69.8%) and 214 (30.2%), 204 (28.7%), 292 (41.1%), according to GOLD 2016. In terms of demographic and clinical characteristics related to A–D groups, there was a significant difference in COPD assessment test (CAT), modified Medical British Research Council (mMRC), the clinical COPD questionnaire(CCQ), age, BMI, education level, smoking history, comorbidities, the course of chronic bronchitis/emphysema, number of exacerbations/hospitalisations in the previous year, treatment protocols, forced expiratory volume in one second (FEV1) % predicted, and FEV1/forced vital capacity (FVC) (p < 0.01). Furthermore, some patients in groups C–D regrouped to groups A–B were all C(1) and D(1) subgroups according to GOLD 2019. Comparing subgroup D(1) with group B, subgroup D(2) and subgroup D(3), it was found that the demography, clinical characteristics and medications of subgroup D(1) were the closest to group B, according to GOLD 2016 (p < 0.01). The disease severity of outpatients with COPD in Hunan Province was more pronounced in group B and D and patients in groups A–D had different demography, clinical characteristics and medications. Subgroup analysis can explain to a certain extent that GOLD2019’s new comprehensive assessment is more reliable than GOLD 2016.
format Online
Article
Text
id pubmed-8760288
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-87602882022-01-18 Subgroup analysis reveals higher reliability of the new comprehensive evaluation of Global Initiative for Chronic Obstructive Lung Disease 2019 Dai, Zhongshang Zeng, Huihui Cui, Yanan Chen, Ping Chen, Yan Sci Rep Article To estimate the severity of the disease in outpatients with chronic obstructive pulmonary disease (COPD) in Hunan Province, China and use the subgroup analysis to evaluate the reliability of the new comprehensive evaluation of Global Initiative for Chronic Obstructive Lung Disease (GOLD). COPD outpatients from 12 medical centers in Hunan Province, China were stratified into groups A–D, and group D patients were further stratified into subgroups D(1)–D(3) according to the GOLD 2016 and 2019 comprehensive assessment. Demography, clinical characteristics and medications were compared among groups. In 1017 COPD outpatients, the distribution from group A to D and subgroup D(1) to D(3) was 41 (4.0%), 249 (24.5%), 17 (1.7%), 710 (69.8%) and 214 (30.2%), 204 (28.7%), 292 (41.1%), according to GOLD 2016. In terms of demographic and clinical characteristics related to A–D groups, there was a significant difference in COPD assessment test (CAT), modified Medical British Research Council (mMRC), the clinical COPD questionnaire(CCQ), age, BMI, education level, smoking history, comorbidities, the course of chronic bronchitis/emphysema, number of exacerbations/hospitalisations in the previous year, treatment protocols, forced expiratory volume in one second (FEV1) % predicted, and FEV1/forced vital capacity (FVC) (p < 0.01). Furthermore, some patients in groups C–D regrouped to groups A–B were all C(1) and D(1) subgroups according to GOLD 2019. Comparing subgroup D(1) with group B, subgroup D(2) and subgroup D(3), it was found that the demography, clinical characteristics and medications of subgroup D(1) were the closest to group B, according to GOLD 2016 (p < 0.01). The disease severity of outpatients with COPD in Hunan Province was more pronounced in group B and D and patients in groups A–D had different demography, clinical characteristics and medications. Subgroup analysis can explain to a certain extent that GOLD2019’s new comprehensive assessment is more reliable than GOLD 2016. Nature Publishing Group UK 2022-01-14 /pmc/articles/PMC8760288/ /pubmed/35031681 http://dx.doi.org/10.1038/s41598-021-04756-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Dai, Zhongshang
Zeng, Huihui
Cui, Yanan
Chen, Ping
Chen, Yan
Subgroup analysis reveals higher reliability of the new comprehensive evaluation of Global Initiative for Chronic Obstructive Lung Disease 2019
title Subgroup analysis reveals higher reliability of the new comprehensive evaluation of Global Initiative for Chronic Obstructive Lung Disease 2019
title_full Subgroup analysis reveals higher reliability of the new comprehensive evaluation of Global Initiative for Chronic Obstructive Lung Disease 2019
title_fullStr Subgroup analysis reveals higher reliability of the new comprehensive evaluation of Global Initiative for Chronic Obstructive Lung Disease 2019
title_full_unstemmed Subgroup analysis reveals higher reliability of the new comprehensive evaluation of Global Initiative for Chronic Obstructive Lung Disease 2019
title_short Subgroup analysis reveals higher reliability of the new comprehensive evaluation of Global Initiative for Chronic Obstructive Lung Disease 2019
title_sort subgroup analysis reveals higher reliability of the new comprehensive evaluation of global initiative for chronic obstructive lung disease 2019
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760288/
https://www.ncbi.nlm.nih.gov/pubmed/35031681
http://dx.doi.org/10.1038/s41598-021-04756-w
work_keys_str_mv AT daizhongshang subgroupanalysisrevealshigherreliabilityofthenewcomprehensiveevaluationofglobalinitiativeforchronicobstructivelungdisease2019
AT zenghuihui subgroupanalysisrevealshigherreliabilityofthenewcomprehensiveevaluationofglobalinitiativeforchronicobstructivelungdisease2019
AT cuiyanan subgroupanalysisrevealshigherreliabilityofthenewcomprehensiveevaluationofglobalinitiativeforchronicobstructivelungdisease2019
AT chenping subgroupanalysisrevealshigherreliabilityofthenewcomprehensiveevaluationofglobalinitiativeforchronicobstructivelungdisease2019
AT chenyan subgroupanalysisrevealshigherreliabilityofthenewcomprehensiveevaluationofglobalinitiativeforchronicobstructivelungdisease2019